teal triangle graphic

R&D Pipeline

R&D Pipeline

Pipeline of Key Proprietary Product Candidates

We have a pipeline of product candidates in development for psychiatric and neurological disorders.

These programs are investigating treatments or indications that have not received approval from a health authority. The information presented is not intended to convey conclusions of safety or efficacy. There is no guarantee that the outcome of these studies will result in approval by a health authority.

Discovery
Preclinical
Phase 1
Phase 2
Phase 3

Olanzapine and samidorphan
- Schizophrenia and Bipolar I Disorder (Pediatric)
  
  Phase 3
Overview
Olanzapine and samidorphan is a once-daily, oral atypical antipsychotic drug approved for adults in the U.S.

Clinical Trials
Olanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT05303064.
ALKS 2680
- Narcolepsy Type 1
  
  Phase 2
- Narcolepsy Type 2
  
  Phase 2
- Idiopathic Hypersomnia
  
  Phase 1
Overview
ALKS 2680 is an investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.
Clinical Trials
ALKS 2680 is currently being evaluated in Vibrance-1, a phase 2 study in adults with narcolepsy type 1, and Vibrance-2, a phase 2 study in adults with narcolepsy type 2.

For more information about these studies, please visit vibrancestudies.com (for U.S. audiences only) or the respective clinicaltrials.gov listings:
- Vibrance-1: clinicaltrials.gov/study/NCT06358950
- Vibrance-2: clinicaltrials.gov/study/NCT06555783
Orexin Agonists
- Neuroscience Indications
  
  Preclinical
- Neuroscience Indications
  
  Preclinical
Overview
Additional orexin 2 receptor agonists are in preclinical research for the treatment of other neurological and psychiatric disorders.

Last updated: December 2024